Wife-and-husband team, J. Jean Cui and Y. Peter Li, launched Blossomhill Therapeutics Inc. in mid-2020 to focus on next-generation, macrocyclic inhibitors against oncology targets. The couple had planned to take some time off to rest and do a little traveling, but then the pandemic hit. “This was a great time [to start a new company],” Cui told BioWorld. “Nothing to do but reading and thinking.”
Blossomhill Therapeutics Inc. have identified 7-azaindazole macrocycles acting as ALK tyrosine kinase receptor (mutant) inhibitors potentially useful for the treatment of cancer.
Blossomhill Therapeutics Inc. has synthesized new indazole-based macrocyclic compounds acting as ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.
The use of tyrosine kinase inhibitors (TKIs) in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) has not produced the same durable clinical benefits observed with next-generation targeted therapies in ALK- and ROS1-rearranged NSCLC. Given the molecular heterogeneity of EGFR-mutant NSCLC, which includes over 100 distinct mutations, there is a continued need for more effective and mutation-specific therapeutic strategies.
Research at Blossomhill Therapeutics Inc. has led to the discovery of new macrocyclic compounds acting as tyrosine kinase inhibitors and reported to be useful for the treatment of autoimmune disease.
Blossomhill Therapeutics Inc. has identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Blossomhill Therapeutics Inc. has divulged macrocyclic compounds acting as epidermal growth factor receptor (EGFR: HER1; erbB1) and EGFR mutant inhibitors reported to be useful for the treatment of cancer.
